Ticagrelor

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Ticagrelor and local guidelines before prescribing.

P2Y12 inhibitor

Mechanism

Reversible P2Y12 receptor antagonist.

Uses

Acute coronary syndrome, post-MI secondary prevention.

Dosing

2 more dose entries from the chapters

Side effects

Bleeding, dyspnoea, bradycardia, raised uric acid and creatinine.

Interactions

Strong CYP3A4 inhibitors and inducers; simvastatin dose limit.

Contraindications and cautions

Active bleeding, prior intracranial haemorrhage, severe liver disease

Monitoring

Bleeding, dyspnoea

Pregnancy and breastfeeding

Avoid

Renal and hepatic impairment

No adjustment

Overdose and reversal

Platelet transfusion not effective; supportive

Special advice

Dyspnoea is usually benign; avoid in prior intracranial haemorrhage; hold before surgery per guidance.

More from the textbook: uses, cautions and other points
Where it is discussed in the book